Lysergic acid diethylamide (LSD) is a partial agonist of D2 dopaminergic receptors and it potentiates dopamine-mediated prolactin secretion in lactotrophs in vitro

Life Sciences

Volumn 63, Issue 3, 1998, Pages 215-222

  Giacomelli, Sabrina ^a,b   Palmery, Maura ^a   Romanelli, Luca ^a   Yan Cheng, C ^b,c   Silvestrini, Bruno ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b ROCKEFELLER UNIVERSITY   (United States)

^c POPULATION COUNCIL   (United States)

Author keywords

Dopaminergic receptors; LSD; Pituitary cells; Prolactin secretion

Indexed keywords

8 BROMO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL; BROMOCRIPTINE; CYPROHEPTADINE; DOPAMINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; LYSERGIDE; PROLACTIN; SEROTONIN; SPIPERONE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC TRANSMISSION; DRUG EFFECT; FEMALE; HYPOPHYSIS CELL; NONHUMAN; PROLACTIN RELEASE; RAT;

2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; ANIMALS; BROMOCRIPTINE; CELLS, CULTURED; CYPROHEPTADINE; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; FEMALE; LYSERGIC ACID DIETHYLAMIDE; PITUITARY GLAND; PROLACTIN; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D2;

EID: 0032511064     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(98)00262-8     Document Type: Article

References (21)

1. 1. F.J. WHITE and J.B. APPEL, Science 216 535-537 (1982).
2. 2. J.B. APPEL, F.J. WHITE and A.M. HOLOHEAN, Neurosci. B. 6 529-536 (1982).
3. 3. R.A. GLENNON, M. TITELER and J.D. MCKENNEY, Life Sci 35 2505-2511 (1984).
4. 4. K.D. BURRIS, M. BREEDING and E. SANDERS-BUSH, J. Pharm. Exp. 258 891-896 (1991).
5. 5. G.J. MAREK and G.K. AGHAJANIAN, J. Pharm. Exp. 278 1373-1382 (1996).
6. 6. M.T. NAKADA, C.M. WIECZOREK and T.C. RAINBOW, Neurosci. Lett. 49 13-18 (1984).
7. 7. P.R. HARTIG, M.J. KADAN, M.J. EVANS and A.M. KROHN, Eur. J. Pharm. 89 321-322 (1983).
8. 8. L. PIERI, H.H. KELLER, W. BURKARD and M. DA PRADA, Nature 272 278-280 (1978).
9. 9. A.M. HOLOHEAN, F.J. WHITE and J.B. APPEL, Eur. J. Pharm. 81 595-602 (1982).
10. 10. M. DA PRADA, A. SANER, W.P. BURKARD, G. BARTHOLINI and A. PLETSCHER, Brain Res. 94 67-73 (1975).
11. 11. H.S. AHN and M.H. MAKMAN, Brain Res. 162 77-88 (1979).
12. 12. S.K. QUADRI and J. MEITES, P. Soc. Exp. M. 137 1242-1243 (1971).
13. 13. H.Y. MELTZER, R.G. FESSLER, M. SIMONOVIC, J. DOHERTY and V.S. FANG, Psychopharmacol. 54 39-44 (1977).
14. 14. S.A. SIGNS, B. LIU, J. WOLFORD and A.J. CARRILLO Mol. Cell. Endoc. 105 183-191 (1994).
15. 15. L.D. VAN DE KAR, P.A. RITTHENHOUSE, Q. LI and A.D. LEVY, Beh. Brain Res. 73 203-208, (1996).
16. 16. S. GIACOMELLI, L. BRAGHIROLI, A. PONZIANELLI, D.W. KOPPENAAL and G. DE FEO, J. Pharm. Pharmacol. 49 319-321 (1997).
17. 17. D. RODBARD, V.B. FADEN, S. KNISLEY and D.M. HUNT, RIA data processing: Logistic method and quality control PB 24622. Natural Technical Information Services, Springfield IL, pp. 1-180 (1975).
18. 18. B. SILVESTRINI, M. PALMERY and C. SEVERINI, Pharm. Res. Comm. 20 435-467 (1988).
19. 19. R.B. McCALL and G.K. AGHAJANIAN, Life Sci. 26 1149-1156 (1980).
20. 20. E. SANDERS-BUSH, K.D. BURRIS and K. KNOTH, J Pharm. Exp. 246 924-928 (1988).
21. 21. L. ZHANG and D.C. DYER, Eur. J. Pharm. 230 115-117 (1993).